The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
TCT 2021 | Future directions of immune cell therapy in lymphoma
Yago Nieto, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, explores the next stages of immunotherapy and cellular therapy for patients with lymphoma, including the use of novel immune cells as well as improving the efficacy of T-cell approaches to prevent T-cell exhaustion and enhance T-cell localization. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
